Skip to content

Author

R. Kurzrock

We have 6 of 107 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

The Multifaceted Roles of STAT6: Implications for Precision Immunotherapeutics

Abstract STAT6, located on chromosome 12, encodes a transcription factor whose SH2 domain is central to its activation. While classically a Th2 mediator, aberrant STAT6 activation is observed in diverse malignancies. This review focuses on the molecular and functional landscape of STAT6, primarily in cancer and tumor i...

Hiba Narvel, D. Nishizaki, S. Kato et al. · 0 citations
Review Open access Sep 2026

Molecular therapy matching score correlates with clinical outcomes: a system for navigating cancer complexity

An algorithmic Matching Score is described that evaluates cancer drugs’/drug combinations’ ability to address a patients’ entire next-generation sequencing/multi-omic-derived molecular profile and underscores the clinical importance of the precision medicine approach that maximizes matching of multiple molecular altera...

Ally Perlina, Subha Krishnan, K. Bush et al. · 0 citations
Review Open access Oct 2026

Evolution of Precision Oncology, Personalized Medicine, and Molecular Tumor Boards.

Evidence is accumulating to support feasibility and survival benefit in patients treated with matched therapy, and the incorporation of molecular targeted therapies and immunotherapy into the perioperative setting requires clinicians to understand the role of the MTB.

Yu Fujiwara, S. Kato, R. Kurzrock · 0 citations
Jul 2026

Abstract IA010: On the right TRACK: Operationalizing a national, patient-driven, decentralized trial offering comprehensive genomic profiling and a molecular tumor board for rare cancers

The TRACK trial provides a scalable decentralized model for equitable access to precision medicine for patients with rare cancers while simultaneously generating data to drive a better understanding of rare cancers that otherwise may have limited treatment options.

J. Palma, Shumei Kato, M. Nikanjam et al. · 0 citations
Review Open access Jul 2026

Anaplastic thyroid cancer: review of precision therapy options and advances.

A patient with advanced BRAF-mutant ATC who recovered with a combination of the anti-PD1 nivolumab and the BRAF V600E targeted drug vemurafenib is shown, indicating further studies using biomarker-based gene- and immune-targeted agents, including in combination, are needed in ATC.

Noor Khalid, R. Kurzrock, Shumei Kato · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.